The minor allele rs2295613(A), protective against systemic lupus erythematosus, makes a differential contribution to the activity of the SLAMF1 gene promoter in T helpers and in regulatory T lymphocytes

SLAMF1 (CD150) is a receptor expressed on various hematopoietic cells and involved in the pathogenesis of autoimmune diseases such as systemic lupus erythematosus (SLE). This disorder is a chronic autoimmune inflammatory disease characterized by dysregulation of B lymphocytes, production of a large number of autoantibodies, and various abnormalities in immune regulation, such as changes in the number and functions of T helper cells and T regulatory (Treg) lymphocytes. Expression of SLAMF1 on T helper cells and B lymphocytes is increased in patients with active SLE. Impaired interaction of SLAMF1 receptors on T and B lymphocytes reduces the production of IL-6 and differentiation of plasmablasts in SLE. In the present work, we performed a functional analysis of single nucleotide promoter polymorphisms rs2295614(A>T) and rs2295613(G>A) of the SLAMF1 gene in the models of T-regulatory lymphocytes (MT-2 cell line) and T helpers (Jurkat cell line). Previously, an association of the rs2295614(A)/rs2295613(G) haplotype with the risk of developing SLE was shown, and it was also demonstrated that the risk haplotype in the promoter region of the SLAMF1 gene increases promoter activity in the Jurkat T cell line. Using reporter analysis, we have shown that the activity of the SLAMF1 promoter containing the minor variant rs2295613(A) increases in MT-2 cells and decreases in Jurkat cells. Based on the analysis of transcriptomes of these cell lines, we suggest that such a differential effect of the protective minor rs2295613(A) variant on promoter activity may be mediated by differential binding of transcription factors: activating MYC/MAX heterodimer in MT-2 cells and repressor MAX/MXD4 in Jurkat cells. Furthermore, both the increased expression of SLAMF1 in regulatory T cells and its decreased expression in T helper cells are likely to impact SLE pathogenesis similarly. These changes could reduce the efficiency of activating signal transmission from T helper cells to B lymphocytes, thereby weakening the autoreactive response of B lymphocytes. Thus, we propose a molecular mechanism mediating the protective role of the minor rs2295613(A) allele in the development of SLE.

1. Alvarado-Sánchez B., Hernández-Castro B., Portales-Pérez D., Baranda L., Layseca-Espinosa E., AbudMendoza C., Cubillas-Tejeda A.C., González-Amaro R. Regulatory T cells in patients with systemic lupus erythematosus. J. Autoimmun., 2006, Vol. 27, no. 2, pp. 110-118.

2. Carroll P.A., Freie B.W., Mathsyaraja H., Eisenman, R.N. The MYC transcription factor network: balancing metabolism, proliferation and oncogenesis. Front. Med., 2018, Vol. 12, pp. 412-425.

3. Correia N.C., Arcangeli M.L., Pflumio F., Barata J.T. Stem Cell Leukemia: how a TALented actor can go awry on the hematopoietic stage. Leukemia, 2016, Vol. 30, no. 10, pp. 1968-1978.

4. Farhangnia P., Ghomi S.M., Mollazadehghomi S., Nickho H., Akbarpour M., Delbandi A.A. SLAM-family receptors come of age as a potential molecular target in cancer immunotherapy. Front. Immunol., 2023, Vol. 14, 1174138. doi: 10.3389/fimmu.2023.1174138.

5. Karampetsou M.P., Comte D., Suárez-Fueyo A., Katsuyama E., Yoshida N., Kono M., Kyttaris V.C., Tsokos G.C. Signaling lymphocytic activation molecule family member 1 engagement inhibits T cell–B cell interaction and diminishes interleukin-6 production and plasmablast differentiation in systemic lupus erythematosus. Arthritis Rheumatol., 2019, Vol. 71, no. 1, pp. 99-108.

6. Linan-Rico L., Hernandez-Castro B., Doniz-Padilla L., Portillo-Salazar H., Baranda L., Cruz-Munoz M.E., González-Amaro R. Analysis of expression and function of the co-stimulatory receptor SLAMF1 in immune cells from patients with systemic lupus erythematosus (SLE). Lupus, 2015, Vol. 24, no. 11, pp. 1184-1190.

7. Link J.M., Hurlin P.J. The activities of MYC, MNT and the MAX-interactome in lymphocyte proliferation and oncogenesis. Biochim. Biophys. Acta, 2015, Vol. 1849, no. 5, pp. 554-562.

8. Pimentel H., Bray N.L., Puente S., Melsted P., Pachter L. Differential analysis of RNA-seq incorporating quantification uncertainty. Nat. Methods, 2017, Vol. 14, no. 7, pp. 687-690.

9. Sato Y., Osada E., Manome Y. Non-canonical NFKB signaling endows suppressive function through FOXP3- dependent regulatory T cell program. Heliyon, 2023, Vol. 9, no. 12, e22911. doi: 10.1016/j.heliyon.2023.e22911.

10. Schwartz A.M., Putlyaeva L.V., Covich M., Klepikova A.V., Akulich K.A., Vorontsov I.E., Korneev K.V., Dmitriev S.E., Polanovsky O.L., Sidorenko S.P., Kulakovskiy I.V. Early B-cell factor 1 (EBF1) is critical for transcriptional control of SLAMF1 gene in human B cells. Biochim. Biophys. Acta, 2016, Vol. 1859, no. 10, pp. 1259-1268.

11. Tsai Y.G., Liao P.F., Hsiao K.H., Wu H.M., Lin C.Y., Yang K.D. Pathogenesis and novel therapeutics of regulatory T cell subsets and interleukin-2 therapy in systemic lupus erythematosus. Front. Immunol., 2023, Vol. 14, 1230264. doi: 10.3389/fimmu.2023.1230264.

12. Uvarova A.N., Zheremyan E.A., Ustiugova A.S., Murashko M.M., Bogomolova E.A., Demin D.E., Stasevich E.M., Kuprash D.V., Korneev K.V. Autoimmunity-Associated SNP rs3024505 Disrupts STAT3 Binding in B Cells, Leading to IL10 Dysregulation. Int. J. Mol. Sci., 2024, Vol. 25, no. 18, 10196. doi: 10.3390/ijms251810196.

13. Wakeland E.K., Liu K., Graham R.R., Behrens T.W. Delineating the genetic basis of systemic lupus erythematosus. Immunity, 2001, Vol. 15, no. 3, pp. 397-408.

14. Yang Y., Han X., Sun L., Shao F., Yin Y., Zhang W. ETS Transcription factors in immune cells and immunerelated diseases. Int. J. Mol. Sci., 2024, Vol. 25, no. 18, 10004. doi: 10.3390/ijms251810004.

15. You Y., Wang Z., Deng G.H., Liu Y., Hao F. Detection and functional evaluation of 262A/T and 188A/G polymorphisms of SLAM gene in patients with systemic lupus erythematosus. J. Rheumatol., 2010, Vol. 37, no. 11, pp. 2268-2272.